Qiagen partners up for Novel Diagnostic against Breast Cancer

26/05/2016 - 2 minutes

Qiagen is partnering up with Therawis to develop a diagnostic test to predict how effective an aggressive chemotherapy will be in patients with high risk breast cancer.

qiagen_therawis_pitx2_breast_cancerA giant in molecular diagnostics, Qiagen is now working in a new diagnostic test that could help guide the treatment of breast cancer.

Now, Qiagen has partnered with Therawis Diagnostics, a Munich-based company focused in oncology and predictive tests. Its most advanced programme is to predict how effective certain chemotherapeutic drugs will be against breast cancer.

The main focus is anthracycline, a drug currently used to treat patients with high-risk breast cancer. This therapy has serious side effects (such as congestive heart failure or leukemia), and has a relatively low response rate in patients – 50% or less.

A particular type of cancer that has a poor prognosis is triple-negative breast cancer (TNBC). Only about 35% of TNBC patients respond to the chemotherapy,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!